Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Infect Dis
Главные авторы: Tapia, Milagritos D., Findlow, Helen, Idoko, Olubukola T., Preziosi, Marie-Pierre, Kulkarni, Prasad S., Enwere, Godwin C., Elie, Cheryl, Parulekar, Varsha, Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Akinsola, Adebayo K., Adegbola, Richard A., Kampmann, Beate, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, Viviani, Simonetta, Tang, Yuxiao, Plikaytis, Brian D., Marc LaForce, F., Carlone, George, Borrow, Ray
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2015
Предметы:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639509/
https://ncbi.nlm.nih.gov/pubmed/26553683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ672
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы